Related references
Note: Only part of the references are listed.Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley et al.
ADVANCES IN THERAPY (2013)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Autocrine functions of VEGF in breast tumor cells Adhesion, survival, migration and invasion
Martine Perrot-Applanat et al.
CELL ADHESION & MIGRATION (2012)
Mammalian target of rapamycin: Biological function and target for novel anticancer agents
Emily B. Borders et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis
Takaaki Fujii et al.
ATHEROSCLEROSIS (2008)
Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2-mediated therapeutic neovascularization - Critical role of the inflammatory/arteriogenic pathway
Takaaki Fujii et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Non-angiogenic functions of VEGF in breast cancer
Arthur M. Mercurio et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2005)
Inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
A Boulay et al.
CLINICAL CANCER RESEARCH (2005)
Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer
M Liu et al.
CANCER RESEARCH (2005)
Essential role of PDGFRα-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo -: Role of PDGFRα during angiogenesis
N Tsutsumi et al.
CIRCULATION RESEARCH (2004)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Epithelial mesenchymal interactions in cancer and development
AM Arias
CELL (2001)
Share Paper
